menu
    • menu
    [{"orgOrder":0,"company":"Pregene","sponsor":"Dr. Reddy\\'s Laboratories","pharmaFlowCategory":"D","amount":"$162.5 million","upfrontCash":"Undisclosed","newsHeadline":"Pregene and Dr. Reddy's Announce License Agreement for Anti-BCMA CAR-T PRG1801 in India","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Autologous anti-BCMA CAR-T therapy","moa":"B-Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Pregene","amount2":0.16,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.16,"dosageForm":"Intravenous Infusion","sponsorNew":"Pregene \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"6","companyTruncated":"Pregene \/ .."},{"orgOrder":0,"company":"Pregene","sponsor":"Bone Therapeutics","pharmaFlowCategory":"D","amount":"$53.6 million","upfrontCash":"$9.7 million","newsHeadline":"Bone Therapeutics to Regain Worldwide Rights to ALLOB","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Termination","leadProduct":"Allogeneic Bone Cell Therapy","moa":"","url1":"","url2":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Pregene","amount2":0.050000000000000003,"therapeuticAreaNew":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Injectable\/Injection","sponsorNew":"Pregene \/ Pregene","highestDevelopmentStatusID":"8","companyTruncated":"Pregene \/ .."}]

    Find Clinical Drug Pipeline Developments & Deals by Pregene

    Menu

    Pregene

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Pregene

                            China arrow
                            Formnext Forum
                            Not Confirmed

                            Pregene

                            China arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allogeneic Bone Cell Therapy

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Study Phase : Phase II

                            Recipient : Bone Therapeutics

                            Deal Size : $53.6 million

                            Deal Type : Termination

                            DEALS_DEV arrow-down

                            Bone Therapeutics to Regain Worldwide Rights to ALLOB

                            Details : ALLOB (allogeneic bone cell therapy) is an allogeneic osteoblastic cell therapy product derived from ex vivo cultured bone marrow cells. It represents a unique, proprietary approach to bone regeneration, which turns undifferentiated stromal cells into bo...

                            Brand Name : ALLOB

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : $9.7 million

                            October 07, 2022

                            Lead Product(s) : Allogeneic Bone Cell Therapy

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Highest Development Status : Phase II

                            Recipient : Bone Therapeutics

                            Deal Size : $53.6 million

                            Deal Type : Termination

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Pregene

                            China arrow
                            Formnext Forum
                            Not Confirmed

                            Pregene

                            China arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Autologous anti-BCMA CAR-T therapy

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Dr. Reddy\\\'s Laboratories

                            Deal Size : $162.5 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Pregene and Dr. Reddy's Announce License Agreement for Anti-BCMA CAR-T PRG1801 in India

                            Details : Shenzhen Pregene Biopharma and Dr. Reddy's Laboratories announce a license agreement whereby Dr Reddy's will acquire the exclusive rights in India for PRG1801, an anti-BCMA CAR-T cell therapy injection based on single domain antibody technology.

                            Brand Name : PRG1801

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            May 13, 2021

                            Lead Product(s) : Autologous anti-BCMA CAR-T therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Dr. Reddy\\\'s Laboratories

                            Deal Size : $162.5 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth